Elevated Endothelin-1 Vasoconstrictor Tone in Prehypertensive Adults

Canadian Journal of Cardiology

Volumn 28, Issue 3, 2012, Pages 347-353

  Weil, Brian R ^a   Westby, Christian M ^a   Greiner, Jared J ^a   Stauffer, Brian L ^a,b,c   DeSouza, Christopher A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE;

ADULT; ARM; ARTERY ENDOTHELIUM; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; MALE; PREHYPERTENSION; RECEPTOR BLOCKING; VASOCONSTRICTION; VASODILATATION;

ACETYLCHOLINE; ADULT; AGED; BLOOD PRESSURE DETERMINATION; CASE-CONTROL STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; NITROPRUSSIDE; PEPTIDES, CYCLIC; PREHYPERTENSION; REFERENCE VALUES; VASOCONSTRICTION; VASODILATION;

EID: 84860918884     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.11.006     Document Type: Article

References (46)

1. Qureshi A.I., Suri M.F., Kirmani J.F., Divani A.A., Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases?. Stroke 2005, 36:1859-1863.
2. Wang Y., Wang Q.J. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004, 164:2126-2134.
3. Vasan R.S., Larson M.G., Leip E.P., Kannel W.B., Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682-1686.
4. Winegarden C.R. From "prehypertension" to hypertension?. Additional evidence. Ann Epidemiol 2005, 15:720-725.
5. Hsia J., Margolis K.L., Eaton C.B., et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007, 115:855-860.
6. Liszka H.A., Mainous A.G., King D.E., Everett C.J., Egan B.M. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005, 3:294-299.
7. Vasan R.S., Larson M.G., Leip E.P., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291-1297.
8. Landmesser U., Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007, 22:316-320.
9. Lerman A., Zeiher A.M. Endothelial function: cardiac events. Circulation 2005, 111:363-368.
10. Weil B.R., Stauffer B.L., Greiner J.J., Desouza C.A. Prehypertension is associated with impaired nitric oxide-mediated endothelium-dependent vasodilation in sedentary adults. Am J Hypertens 2011, 24:976-981.
11. Giannotti G., Doerries C., Mocharla P.S., et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 2010, 55:1389-1397.
12. Plavnik F.L., Ajzen S.A., Christofalo D.M., Barbosa C.S., Kohlmann O. Endothelial function in normotensive and high-normal hypertensive subjects. J Hum Hypertens 2007, 21:467-472.
13. Luscher T.F., Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102:2434-2440.
14. Miyauchi T., Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391-415.
15. Cardillo C., Campia U., Kilcoyne C.M., Bryant M.B., Panza J.A. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002, 105:452-456.
16. Cardillo C., Kilcoyne C.M., Waclawiw M., Cannon R.O., Panza J.A. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999, 33:753-758.
17. Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784-790.
18. Nakov R., Pfarr E., Eberle S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15:583-589.
19. Guarda E., Myers P.R., Brilla C.G., Tyagi S.C., Weber K.T. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res 1993, 27:1004-1008.
20. Spieker L.E., Flammer A.J., Luscher T.F. The vascular endothelium in hypertension. Handb Exp Pharmacol 2006, 249-283.
21. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
22. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32:S62-S67. American Diabetes Association.
23. Fedder D.O., Koro C.E., L'Italien G.J. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002, 105:152-156.
24. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals, Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
25. Lohman T.G., Roche A.F., Mortorelli R. Anthropometric Standardization Reference Manual 1988, Human Kinetics, Champaign, IL.
26. Van Guilder G.P., Stauffer B.L., Greiner J.J., Desouza C.A. Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists. Am J Physiol Heart Circ Physiol 2008, 294:H1685-H1692.
27. Van Guilder G.P., Westby C.M., Greiner J.J., Stauffer B.L., DeSouza C.A. Endothelin-1 vasoconstrictor tone increases with age in healthy men but can be reduced by regular aerobic exercise. Hypertension 2007, 50:403-409.
28. Nohria A., Garrett L., Johnson W., Kinlay S., Ganz P., Creager M.A. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 2003, 42:43-48.
29. Weil B.R., Westby C.M., Van Guilder G.P., Greiner J.J., Stauffer B.L., Desouza C.A. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011, 301:H689-H695.
30. Egan B.M., Lackland D.T., Jones D.W. Prehypertension: an opportunity for a new public health paradigm. Cardiol Clin 2010, 28:561-569.
31. Fuchs F.D. Prehypertension: the rationale for early drug therapy. Cardiovasc Ther 2010, 28:339-343.
32. Kuvin J.T., Karas R.H. Clinical utility of endothelial function testing: ready for prime time?. Circulation 2003, 107:3243-3247.
33. Bohm F., Jensen J., Svane B., Settergren M., Pernow J. Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can J Physiol Pharmacol 2008, 86:745-751.
34. Bourque S.L., Davidge S.T., Adams M.A. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol 2011, 300:R1288-R1295.
35. Callera G.E., Touyz R.M., Teixeira S.A., et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003, 42:811-817.
36. Iglarz M., Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007, 50:621-628.
37. Schiffrin E.L. Vascular endothelin in hypertension. Vascul Pharmacol 2005, 43:19-29.
38. Manios E., Tsivgoulis G., Koroboki E., et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke 2009, 40:1515-1518.
39. Kaplan N.M. Treating prehypertension: a review of the evidence. Curr Hypertens Rep 2008, 10:326-329.
40. Elliott W.J., Black H.R. Prehypertension. Nat Clin Pract Cardiovasc Med 2007, 4:538-548.
41. Casino P.R., Kilcoyne C.M., Cannon R.O., Quyyumi A.A., Panza J.A. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol 1995, 75:40-44.
42. McVeigh G.E., Brennan G.M., Johnston G.D., et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992, 35:771-776.
43. Campia U., Cardillo C., Panza J.A. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation 2004, 109:3191-3195.
44. Grubbs A.L., Anstadt M.P., Ergul A. Saphenous vein endothelin system expression and activity in African American patients. Arterioscler Thromb Vasc Biol 2002, 22:1122-1127.
45. Wagner O.F., Christ G., Wojta J., et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992, 267:16066-16068.
46. Cardillo C., Campia U., Iantorno M., Panza J.A. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004, 43:36-40.